MFN News Items – Page 2

iZafe Group presenterade på Stora Aktiedagarna

iZafe Groups VD Anders Segerström presenterade bolaget på Aktiespararnas evenemang Stora Aktiedagarna. Under presentationen lyfte Anders Segerström fram bolagets starka framtidsutsikter, med en prognos som visar att de årliga återkommande intäkterna (ARR) förväntas öka från 0,3 MSEK 2023 till 85,5 MSEK 2029.

Presentationens höjdpunkter inkluderade:

Framtidsprognos: iZafe Group visar på stark organisk tillväxt och har etablerat en hållbar affärsmodell med fokus på att minska vårdkostnader och förbättra patientsäkerheten. Prognosen visar att bolagets årliga återkommande intäkter (ARR) förväntas öka enligt följande:
- 2023: 0,3 MSEK
- 2024: 1,7 MSEK (+326%)
- 2025: 10 MSEK (+352%)
- 2026: 22,5 MSEK (+125%)
- 2027: 42,3 MSEK (+69%)
- 2028: 63,9 MSEK (+41%)
- 2029: 85,5 MSEK (+29%)
Lansering av Dosell 3.0: En uppgraderad version av bolagets medicindispenser med en kraftfullare processor och nya funktioner för att ytterligare förbättra medicineringshantering och patientföljsamhet. Denna uppgradering syftar till att stödja såväl vårdpersonal som patienter genom en effektivare och säkrare lösning.
Marknadsutveckling: Betydande framsteg har gjorts på flera europeiska marknader, inklusive Sverige, Nederländerna och Spanien. iZafe Group arbetar aktivt med att expandera sin närvaro och etablera starka partnerskap för att möta det ökande behovet av lösningar för medicineringshantering.

Presentationens innehåll och strategiska insikter visar iZafe Groups engagemang i att driva innovation och tillväxt inom hälso- och sjukvårdssektorn.

Du kan se presentationen i sin helhet här.

Om iZafe Group AB (publ.)

iZafe Group är ett Life Science bolag som bedriver forskning, utveckling och marknadsföring av digitala medicinska lösningar och tjänster för tryggare läkemedelshantering i hemmet.

Bolaget leder utvecklingen av digital läkemedelsdispensering genom läkemedelsroboten Dosell samt SaaS-lösningen och den uppkopplade dosettasken Pilloxa. Bolagets lösningar minskar risken för felmedicinering i hemmet, ökar följsamheten, avlastar den offentliga vården, ökar livskvaliteten för patienter samt skapar en tryggare miljö för anhöriga.

Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group säljer primärt via väletablerade partners som redan besitter långa och djupa kundrelationer med de prioriterade kundgrupperna. Huvudkontoret ligger i Stockholm.

iZafe Group AB är noterat på Nasdaq First North Growth Market sedan 2018. Mangold Fondkommission AB är bolagets Certified Adviser. Ytterligare information finns på www.izafegroup.com

iZafe Group presenterade på Stora Aktiedagarna

Aktiedagarna

Increased Demand and Successful Launch – iZafe Group Strengthens Its Position

February was an intense and forward-looking month for iZafe Group. We continue to accelerate our growth and strengthen our market presence through strategic partnerships and expansion in multiple key markets. Despite seasonal variations, the number of active Dosell units increased by 9%, demonstrating continued strong demand and stable user growth. Spain successfully launched Dosell, while in Sweden, we rapidly expanded with new municipalities implementing our solution. At the same time, our establishment in the Netherlands progressed, and we look forward to further sales growth through upcoming trade fairs in both Spain and the Netherlands.

Spain: Official Launch and Initial Market Activities
After an intensive preparation phase, we have now officially launched Dosell in Spain! Spain has one of the largest healthcare markets in Europe, with over 22,000 pharmacies and an aging population driving demand for digital medication management solutions. This presents significant growth potential and an opportunity to establish Dosell as a leading solution in the market.
Our partner Ti-Medi has initiated marketing efforts by introducing the Savioo platform to all of its 1,500 pharmacies via email and through direct visits to pharmacies in multiple cities, including Barcelona, Girona, Lleida, Granollers, and Madrid. They currently produce dose sachets for 200,000 users, highlighting the significant potential for Dosell in the Spanish market.
To further strengthen our presence, we plan to gain media exposure in the near future, which will open new doors and increase awareness of Dosell in Spain. At the same time, Ti-Medi will be showcasing the Savioo concept along with Dosell at a major trade fair in Barcelona this March, providing additional visibility and opportunities to reach more industry players.

Sweden: Four New Municipalities in Operation and More on the Way
We launched Dosell in four new municipalities in February, while also conducting training sessions for two additional municipalities that plan to implement Dosell in March. Additionally, six new municipalities have expressed interest in adopting Dosell, with four of them already scheduling startup meetings in March and planning to activate their first units in April.
This represents a faster growth rate in terms of the number of municipalities than initially planned. Despite the positive development, we recognize that some challenges remain, particularly regarding the speed of implementation and initial volumes. While we have successfully introduced Dosell in multiple new municipalities in Sweden, the initial deployment is still relatively small-scale. To enhance scalability, we are focusing on improving training efforts for healthcare staff and simplifying the ordering process. However, municipalities plan to increase the number of units over time, reinforcing our strategy and our partners’ efforts to scale up Dosell’s implementation across Sweden.
Some of the feedback we have received from users and staff:

User: “I don’t have to think anymore! Finally, I get my medication at the right time, and when it lights up and beeps, I know it's time to take it.”
Healthcare Staff: “If a user hasn’t taken their medication, a simple phone call is enough to follow up—we don’t have to make a home visit.”
Healthcare Staff: “We chose Dosell as our medication dispenser because it is so simple and fits perfectly with all our municipality’s needs.”

The Netherlands: Stable Growth and Expanding Pipeline
Our market in the Netherlands continues to develop positively, with steadily increasing demand. Our partner's pipeline of new customers is growing, and we anticipate a high activation rate of Dosell units throughout the spring. Their investment in Dosell continues to yield results and is creating a stable platform for future expansion.
Additionally, our partner will be showcasing Dosell at a major trade fair in the Netherlands in April, which we believe will drive an even greater increase in sales.
We recommend following our partner’s journey in the Netherlands through their LinkedIn page, TCCN, for the latest updates and market developments.

Expansion and New Partnerships
Throughout February, we engaged in several exciting discussions with potential new partners in emerging markets. Moving forward, our strategy is to select partners with the best conditions for scaling Dosell on a larger scale. It is crucial to collaborate with organizations that understand how to implement digital technology and manage the necessary transformation processes required for successfully adopting Dosell.

We look forward to continued positive development in March and to building on the strong foundation we have established for our growth. We appreciate your engagement and look forward to sharing more progress in the upcoming updates!

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Increased Demand and Successful Launch – iZafe Group Strengthens Its Position

Apotek Dospåsar Kund

iZafe Group’s Board Member Magnus Engman Purchases 200,000 Shares

iZafe Group's board member, Magnus Engman, acquired 200,000 B-shares in the company on February 26, at a total value of 52,459 SEK (0.262 SEK per share).

The acquisition is a clear signal of Magnus long-term confidence in iZafe's strategy and future potential. His total holding now amounts to 200,000 B-shares.

"I see great potential in iZafe's continued development and want to demonstrate my commitment by investing in the company. We have a clear growth strategy, and I am convinced that we are creating long-term value for our shareholders," says Magnus Engman.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group's Board Member Magnus Engman Purchases 200,000 Shares

Magnus Engman

Launch of Dosell sales in Spain – A groundbreaking solution to improve medication adherence

iZafe Group AB ("iZafe Group") proudly announces the sales launch of Dosell in Spain through a strategic partnership with Ti-Medi, a leading player in pharmaceutical technology in Southern Europe. The launch and commercialization of Dosell, under the brand name Savioo Home, mark a significant milestone in the effort to enhance medication adherence and improve the quality of life for patients with chronic diseases.

Dosell has already established itself as an effective solution in countries such as Sweden and the Netherlands, helping users take the right medication at the right time. Through the partnership with Ti-Medi, Dosell will now be available to the Spanish market, integrating with Ti-Medi’s existing network of over 1,500 pharmacies that utilize their packaging technology for pre-dosed medications.
With Dosell, patients using Savioo Home will receive reminders to take their medication, and if they fail to do so on time, an automatic SMS alert will be sent to relatives or caregivers. This feature ensures a higher level of safety and security for both patients and their loved ones.

A Strategic Partnership for the Future
"We see tremendous potential in the Spanish market and are proud to launch Dosell through our collaboration with Ti-Medi. This is an important step in our international growth journey and our ambition to become a global leader in medication adherence," says Anders Segerström, CEO of iZafe Group.

"At Ti-Medi, we strive to provide technological solutions that simplify patients’ lives and optimize the work of healthcare professionals. Savioo Home not only automates medication management at home but also enhances security for patients, relatives, and pharmacists. This enables more precise monitoring and better adherence to treatment. We believe that the future of healthcare lies in digitalization and tools that increase safety, convenience, and trust – and Savioo Home is a major step in that direction," Says Rafa Tibau, Pharmacist and Co-founder of Ti-Medi

About Ti-Medi
Ti-Medi is a pioneer in pharmaceutical technology in Southern Europe, serving more than 1,500 pharmacies with advanced packaging and dosing solutions. The company’s mission is to enhance medication adherence and make healthcare more accessible and efficient. Read more at ti-medi.com

For more information about Savioo Home and how it can improve medication adherence and patient safety, visit the website savioo.com

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Launch of Dosell sales in Spain – A groundbreaking solution to improve medication adherence

SaviooHome

iZafe Group Q4 Interim Report, October-December 2024 and new forecast

iZafe Group AB (publ.) presents today, February 14, its report for the fourth quarter.

Financial Performance in Summary

Total revenue for the quarter amounted to 2,751 (1,052) TSEK, more than doubling compared to the same period last year. The increase is primarily driven by hardware sales to the Netherlands, which is expected to generate recurring revenue in 2025 as the market establishes itself and implementation progresses.
Operating result (EBIT) for the quarter amounted to -5,697 (-20,475) TSEK
Operating result before depreciation and amortization (EBITDA) for the quarter amounted to -4,714 (-3,386) TSEK.
Result after financial items for the quarter amounted to -5,908 (-20,389) TSEK.
Cash flow from operating activities for the quarter amounted to -178 (-1,946) TSEK.
Earnings per share for the quarter before/after dilution amounted to -0.02 (-0.06) SEK.
Equity per share at the end of the period amounted to 0.04 (0.09) SEK.
The solidity at the end of the period amounted to 40.1 (73.2) percent.

Significant events during the quarter

iZafe Group AB launched Dosell in Spain in collaboration with Ti Medi. At an event in Granada, Dosell was presented to Ti Medi’s network of 1,400 pharmacies. The launch marks a significant milestone, making Dosell commercially available in Spain, with the first units expected to be in use soon. The partnership aims to improve medication management and patient adherence.
iZafe Group received an order for 1,000 Dosell units from its Dutch distributor TCCN, valued at approximately 3,000 TSEK. Deliveries will take place in two phases during 2024 and 2025, with expected recurring revenue of up to 400 TSEK per month. The order strengthens iZafe’s revenue model and reinforces Dosell’s position in the Dutch market.
iZafe Group has certified Dosell for integration with Enovation UMO, a leading healthcare platform in 18 countries. The certification enhances Dosell’s market position, facilitates easier implementation in the Netherlands, and opens opportunities for expansion into additional markets.

Significant events after the end of the quarter

iZafe Group has conducted a directed share issue of approximately 9.2 MSEK through the issuance of 46.15 million B-shares at a subscription price of 0.20 SEK per share. The capital will be used to strengthen working capital, accelerate growth, and support the expansion of Dosell and Pilloxa into new markets.
iZafe Group has started 2025 strong, with a 25% increase in billable Dosell units, approaching 1,000 active devices. Growth is driven by rising demand in Sweden, Norway, and the Netherlands, while the launch in Spain is planned for February. Product improvements and the recently completed 9.2 MSEK share issue further strengthen the company’s growth and goal of achieving cash flow positivity.

Forecast
In this report, we present a forecast graph illustrating our expected growth in both ARR and active Dosell units over the coming years. The forecast is based on our current markets and key performance indicators, outlining a clear path toward an exponential increase in recurring revenue as more units become activated. By the end of 2024, our ARR reached approximately 1.7 MSEK, reflecting a 326% increase compared to the previous year.

In 2025, this growth is expected to accelerate further, with ARR projected to reach 10 MSEK by year-end, a 352% increase. Beyond that, ARR is expected to continue growing rapidly, more than eightfold by 2029, when we anticipate exceeding 85 MSEK. We will track this forecast on a quarterly basis to provide our shareholders with a clear view of our actual progress and how we are advancing toward our financial goals.

	2023	2024	2025	2026	2027	2028	2029
ARR (MSEK)	0.3	1.7	10	22.5	42.3	63.9	85.5
Growth of Dosells	0%	467%	488%	125%	88%	51%	34%

Comments from the CEO
2024 has been a pivotal year for iZafe Group. We have transitioned from developing our product and establishing market conditions to now generating tangible financial results. With a 437% increase in revenue compared to 2023, we see a clear growth trend driven by rising demand for our solutions. Our business model is beginning to demonstrate its strength through recurring revenue, and we have surpassed 2 million SEK in ARR. Our goal for the year is to reach our milestone of 10 million SEK in ARR.

Throughout the year, we have sold 2,500 Dosell units, with growth primarily driven by hardware sales to the Netherlands. Although hardware margins are low, this provides a strategic foundation for future profitability. The true value-creation phase occurs when the units are activated and start generating high-margin recurring license revenue, directly boosting our ARR. We are now approaching an important milestone of 1,000 active dispensing units, which strengthens the stability of our product and business model while contributing to an increasing stream of recurring revenue.

In this report, we present a forecast graph illustrating our expected growth in both ARR and the number of active Dosell units over the coming years. The forecast is based on our current markets and key performance indicators, outlining a clear path toward an exponential increase in recurring revenue as more units become activated. By the end of 2024, our ARR reached approximately 1.7 MSEK, reflecting a 326% increase compared to the previous year.

In 2025, this growth is expected to accelerate further, with ARR projected to reach 10 MSEK by year-end, a 352% increase. Beyond that, ARR is expected to continue growing rapidly, more than eightfold by 2029, when we anticipate exceeding 85 MSEK. We will track this forecast on a quarterly basis to provide our shareholders with a clear view of our actual progress and how we are advancing toward our financial goals.

However, it is important to understand that there is a time lag between ordering hardware and when the units start generating recurring revenue. The production and delivery process must be managed, partners need to be trained, and they must ensure full control over the implementation process. Additionally, customer satisfaction is crucial for achieving stable, long-term growth.

This is particularly relevant when entering new markets and establishing new partnerships. We have already passed this phase in the Netherlands and Sweden, while Spain and Norway are expected to do so during the spring. Spain is set for a launch in February, with Norway expected to follow shortly after. These markets represent a significant opportunity to further increase our ARR and strengthen our position in digital medication management. Beyond this, we aim to expand into additional new markets to continue our growth journey.

Market Potential for Dosell
Dosell operates within an existing and growing market—individuals who receive their medication pre-packaged in dose pouches. For Dosell to be implemented in a new market, an established dose pouch infrastructure is required, where Dosell integrates at the final stage of the process to digitize healthcare and enhance medication safety. The markets we currently operate in have a stable and expanding dose pouch market, and forecasts indicate that this trend will continue as more countries recognize the benefits of this distribution method.

The global trend is clear—the dose pouch market is steadily growing across Europe and the U.S., becoming increasingly standardized as a safe and efficient way to distribute medication. By adapting Dosell to different types of dose pouches, particularly in the Netherlands, we have developed a unique, flexible, and scalable solution that enables faster entry into new markets while significantly lowering the barriers to expansion.

With a significantly reduced time-to-market, we can now implement Dosell much faster, having eliminated technical barriers. Adaptations to new markets now primarily focus on optimizing customer journeys and meeting local regulatory requirements.

To illustrate our market potential, we present an estimate of the number of patients currently receiving their medication in dose pouches across our focus markets:

Sweden: 300,000 patients
Norway: 150,000 patients
Netherlands: 600,000 patients
Spain: 200,000 patients at Ti Medi, with an annual growth rate of 10%

With an established presence in these markets and proven demand, we see significant opportunities to continue scaling Dosell internationally and strengthening our position as a leading player in digitalized medication management.

Enhanced Investor Relations and Shareholder Communication
We have intensified our investor relations communication to provide shareholders and investors with a more transparent and continuous insight into our growth journey. Through our monthly newsletter, we regularly share updates on our progress, strategic initiatives, and market expansion, fostering a closer dialogue with our stakeholders.

The directed share issue of 9.2 MSEK provides the foundation to accelerate growth by increasing the activation of Dosell units and expanding into new markets. At the same time, we continue to focus on strict cost control and operational efficiency, aiming to achieve cash flow positivity and build a long-term profitable business.

Future Prospects
We have built a robust and sustainable business model, where our products, partnerships, and market strategies work together to drive long-term profitable growth. In 2025, our focus is to:

Increase ARR by boosting the activation rate of already sold units and accelerating implementation on existing markets.
Establish and expand strategic partnerships in both new and existing markets to drive growth.
Maximize recurring revenue by optimizing our business model and adding value-enhancing services for existing Dosell units.
Strengthen collaborations with municipalities and healthcare providers to reinforce our market position and ensure stable, predictable growth.

We see a clear path forward, where the expansion and scaling of our license model will continue to fuel our growth. With an increasing ARR and a more stable revenue structure, we anticipate strong momentum in healthcare digitalization through automated medication management. We firmly believe that Dosell has the potential to capture a significant share of this market and establish itself as a leading solution in digital medication management.

The foundation is in place, and we are now entering a growth phase, where our focus is on scalability and operational efficiency.

I would like to conclude by expressing my gratitude to our amazing employees, partners, and shareholders for your dedication and support. It is because of you that we can continue to revolutionize medication management on a global scale.

Thank you for being part of our journey.

Anders Segerström
Chief Executive Officer, iZafe Group

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Interim Report Q4 2024

CEO interview

Q4 Rapport Omslag

Strong Start to 2025 – iZafe Group Accelerates Dosell’s Growth

2025 has started on a positive note for iZafe Group, with steady growth in Dosell and increasing demand across multiple markets. To provide better insights into our journey and progress, we are launching a monthly newsletter to share more frequent updates on developments behind the scenes.

If you are not yet receiving these updates via email, be sure to subscribe at the bottom of our website or through the link in our latest LinkedIn post. Follow us on LinkedIn for continuous updates.

Continuous Growth and Key Milestones
The number of billable Dosell units increased by 25% from December to January, a clear sign that our strategy and partnerships are driving demand.

Our growth is still from a smaller scale, but it is steadily increasing, bringing us closer to a key milestone of 1,000 active Dosell units in use. We expect to reach this soon, marking a significant step in our expansion.

Our business model is based on partners purchasing and stocking Dosell, ensuring cost coverage at the time of sale. The long-term value is generated when the units are activated, creating a recurring monthly revenue stream.

We have already shipped 2,500 Dosell units to our partners, who are experiencing strong demand and expect to activate them within 3–6 months. This increasing activation rate drives our revenue stream, creating a stable and scalable business model.

Sweden: Strong Momentum in VGR and More Municipalities Adopting Dosell
Dosell usage in Västra Götaland Region (VGR) has increased by 18% since December, and interest from municipalities continues to grow. We now have seven new municipalities scheduled for implementation in Q1, both within and outside VGR.

Our partners are actively driving Dosell through existing framework agreements, which accelerates deployment. To meet rising demand and support municipalities with implementation, we will host a webinar for VGR municipalities on March 6 in collaboration with ATEA.

At the MVTe trade fair, Dosell continued to generate strong interest from municipalities and private healthcare providers. Several follow-up meetings are scheduled in February.

Here are just a few comments from Swedish municipal staff, caregivers, and users about Dosell:

"We placed a Dosell with a user who was very skeptical at first. But after just a few days, she was thrilled that she could manage her medication independently while knowing that home care had full control in case she forgot."

"Our municipal staff was highly impressed after seeing Dosell presented. Compared to the larger, more complicated devices we previously used, Dosell will greatly simplify daily work."

"It is so easy to learn!"

"Using Dosell was the best decision we made. My father feels secure, and I receive alerts if anything deviates."

"When many other things started to become difficult due to memory loss, medication management continued to function thanks to Dosell."

Norway: Faster Implementation Through Partnerships
In Norway, we have partnered with Randstad to accelerate implementations and ensure optimal Dosell usage throughout contract periods.
In January, we conducted a comprehensive training session with Hepro, Careium AS, and Randstad to ensure a smooth rollout and equip their sales teams with the right tools for driving adoption.

Netherlands: Stable and Long-Term Growth
The Netherlands continues to be a key market with steady growth in Dosell adoption. Our partner has successfully integrated Dosell into its own platform, "Dispenze", which has been highly appreciated by customers. More organizations are now replacing competing solutions with Dosell.

A testament to our partner’s long-term commitment is their investment in a Dosell showroom, office, and branded delivery vehicles.

Follow TCCN on LinkedIn for regular insights and updates on how Dosell is used in the Netherlands.

Spain: Launch Around the Corner
Ti-medi has developed a comprehensive system and e-commerce solution to ensure a successful Dosell launch in Spain. The process has taken longer than expected, but we anticipate the launch happening in February.

Product Development: Improvements Drive Demand
Over the past year, we have released 13 software versions, and we are soon launching version 14, which includes significant enhancements.

Our goal has always been clear: Dosell should be simple and reliable for users, while we continuously improve refill processes, integrations, and the overall experience for caregivers and partners.

These ongoing improvements have been key to the growth we see today. Dosell is now more efficient than ever, which in turn drives increased demand.

Capital Raise and Focus on Profitability
We would also like to take this opportunity to thank our major shareholders for their support in the directed share issue of approximately SEK 9.2 million.

This capital injection strengthens our ability to accelerate growth while maintaining a clear focus on cost efficiency and achieving cash flow profitability.

We look forward to sharing more details in our upcoming quarterly report next week – stay tuned!

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Strong Start to 2025 – iZafe Group Accelerates Dosell's Growth

Kvartalsrapport

iZafe Group AB has completed a directed share issue of B shares amounting to approximately SEK 9.2 million

The Board of Directors of iZafe Group AB (“iZafe” or the “Company”) has today, based on the authorization granted by the Annual General Meeting on May 30, 2024, resolved on a directed share issue of 46,150,000 B shares at a subscription price of SEK 0.20 per B share (the “Directed Share Issue”). Through the Directed Share Issue, the Company will raise approximately SEK 9.2 million before deductions for set-offs and transaction-related costs. The Directed Share Issue was targeted at a group of Swedish and international investors, including Gästrike Nord Invest AB, WARDCO Invest AB, the Spanish partner JUNIORFARMA S.L., and Exelity AB.

The Directed Share Issue
The Board of Directors of iZafe has today resolved to carry out a directed share issue of 46,150,000 B shares at a subscription price of SEK 0.20 per B share, raising approximately SEK 9.2 million before loan set-offs and transaction-related costs. Loan set-offs amount to a total of approximately SEK 0.5 million. The Directed Share Issue was resolved based on the authorization granted by the Annual General Meeting on May 30, 2024. The subscription price of SEK 0.20 corresponds to a discount of approximately 5.2 percent compared to the volume-weighted average price (VWAP) of the Company’s share on Nasdaq First North Growth Market over the past ten (10) trading days up to and including January 13, 2025. The Directed Share Issue was targeted at a group of Swedish and international investors, including Gästrike Nord Invest AB, WARDCO Invest AB, the Spanish partner JUNIORFARMA S.L., and Exelity AB. The Company intends to use the net proceeds from the Directed Share Issue to strengthen its working capital to accelerate the Company’s continued growth.

The subscription price was determined through arm’s length negotiations between the Company and the subscribers, based on the current market price of iZafe’s share. The Directed Share Issue also provides an opportunity to capitalize on the current interest in the Company’s shares among the subscribers at a price aligned with the prevailing share price. Against this background, the Board considers the subscription price to reflect current demand and market conditions and, therefore, to be market-based.
The Directed Share Issue will increase the number of shares in iZafe by 46,150,000, from 275,586,171 to 321,736,171. The number of votes in the Company will increase by 46,150,000, from 280,986,171 to 327,136,171. The Company’s share capital will increase by SEK 9,230,000, from SEK 55,117,234.20 to SEK 64,347,234.20. The Directed Share Issue entails a dilution of approximately 14.3 percent of the total number of shares and approximately 14.1 percent of the total number of votes in iZafe.
The subscribers in the Directed Share Issue include several existing and long-term shareholders, such as Gästrike Nord Invest AB, WARDCO Invest AB, JUNIORFARMA S.L., Filippa Lindström, Eva Redhe, Fredrik Sjödin, Cecilia Kragsterman, and Pia Engholm, as well as new investors such as Exelity AB, Jimmie Landerman, and Klas Zetterman. The shares in the Directed Share Issue have been subscribed for and allocated.

Reason for Deviation from Shareholders’ Preferential Rights
The purpose of the Directed Share Issue and the reason for deviating from shareholders’ preferential rights is to conduct a capital raise in a time- and cost-efficient manner. The Board has evaluated the possibility of conducting a rights issue as a first option. After weighing the advantages and disadvantages of a rights issue compared to a directed share issue, the Board concluded that a rights issue (i) would be significantly more time-consuming, potentially causing the Company to miss out on growth opportunities, (ii) would result in substantially higher costs for the Company, primarily related to underwriting syndicates and legal expenses, (iii) would expose the Company to greater market volatility, and (iv) would likely need to be conducted at a lower subscription price, resulting in greater dilution, which would be detrimental to all shareholders.
The Directed Share Issue also provides an opportunity to capitalize on the current interest in the Company’s shares among the subscribers at a price aligned with the prevailing share price. Considering the above and after thorough deliberation, the Board has determined that the Directed Share Issue is the most advantageous financing option for iZafe and is in the interest of both shareholders and the Company.
The subscription price in the Directed Share Issue has been determined through arm’s length negotiations with the investors, based on the prevailing share price of the Company’s B shares. Additionally, the Board has ensured the subscription price’s market-based nature in consultation with financial advisors, considering current market conditions and previously indicated price levels in discussions with potential investors. According to the Board’s assessment, the market basis of the subscription price has been ensured through this procedure.
The inclusion of existing shareholders in the Directed Share Issue was both part of the negotiations with new investors and deemed strategically prudent by the Board to include these longstanding and committed shareholders in the Directed Share Issue.

Comment from iZafe’s CEO, Anders Segerström, on the Directed Share Issue:
“The Directed Share Issue is a strategic step to accelerate our growth and strengthen our market position. The strong interest from both Swedish and international investors reflects confidence in our vision to revolutionize medication management through innovative solutions like Dosell and Pilloxa. We look forward to continuing the development of our products and expanding our global reach.”

Subscribers in the Directed Share Issue:
Cecilia Kragsterman, Exelity AB, Eva Redhe, Filippa Lindström, Fredrik Sjödin, Gästrike Nord Invest AB, Jimmie Landerman, JUNIORFARMA S.L., Klas Zetterman, Pia Engholm, and WARDCO Invest AB.

Advisors
Partner Fondkommission AB acts as financial advisor and issuing agent in connection with the Directed Share Issue.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group AB has completed a directed share issue of B shares amounting to approximately SEK 9.2 million

Affärer Partners

The Year in Review: Reflections from iZafe Group’s CEO on 2024

2024 has been a transformative year for iZafe Group, where we have laid a strong foundation for the future. We have multiplied our net revenue, delivered over 500 Dosell units to Spain, and are approaching 2,000 units in the Netherlands. The number of units that deliver the right medication at the right time daily has increased by approximately 500% compared to 2023, confirming that our solutions meet market needs and create real value.

Our partners have purchased hardware with the expectation of implementing these units within a relatively short period, which strengthens our business model of generating recurring monthly revenue.

The launch of Dosell 3.0 marks a milestone with improved functionality and integration. At the same time, we have changed production partners and built efficient production workflows, making us ready to scale up production to meet increasing demand and ensure high quality in every delivery. This work has laid a solid foundation for continued success.

Our innovative efforts have led to several new integrations, such as with Enovation UMO, and strong collaborations with partners like TCCN in the Netherlands and Ti Medi in Spain. These advancements reinforce Dosell as a global leader in health technology, providing solutions that enhance safety and independence for both users and healthcare staff. In Sweden, we have successfully implemented Dosell in numerous municipalities. Our solutions have been appreciated for their user-friendliness, safety, and ability to prevent medication errors. This has not only improved user independence but also streamlined the work of healthcare professionals. This success underscores Dosell's central role in digitalizing and optimizing healthcare at the municipal level.

Looking Ahead to 2025 With a solid foundation in place, we look forward to accelerating our growth. Our pipeline is strong, and we expect 2025 to build on the successes of this year. We plan to further expand Dosell’s presence while giving Pilloxa a central role in our portfolio. These initiatives will enable more innovative solutions and strengthen our position as a leader in health technology. We aim to continue creating value for our customers and shareholders through sustainable and profitable growth.

Thank You for Your Support I would like to extend my heartfelt thanks to our employees, partners, and shareholders. It is through your dedication and commitment that we can continue building a brighter future for healthcare and for iZafe Group. We look forward to 2025 with great ambition and strong confidence in our shared potential.

With warmth and appreciation,
Anders Segerström CEO, iZafe Group

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

The Year in Review: Reflections from iZafe Group’s CEO on 2024

Dosell Karta

iZafe Group AB Strengthens Global Position with UMO Certification for Dosell

iZafe Group AB announces that its product, Dosell, is now certified for integration with Enovation UMO, the monitoring solution for medical service centres. Enovation UMO is part of Enovation Platform, a leading platform for digital care and collaboration used in over 18 countries. This certification marks a significant milestone for iZafe and enables strategically important expansion in both established and new markets.

A Long-Awaited Solution for Dutch Partners
The certification has been highly anticipated by iZafe's partners in the Netherlands, where Enovation UMO is a well-established standard in healthcare. These partners have been eager to begin selling Dosell and can now leverage the seamless integration with the UMO platform. This ensures that Dosell not only complements but also enhances their offering by providing a comprehensive solution for medication management, alarms, and other digital healthcare services within the same platform.

"Creating a Unique Market Position"
"This certification is a critical milestone for iZafe and our partners, especially in the Dutch market, where interest in Dosell is substantial," says Anders Segerström, CEO of iZafe Group AB. "Dosell is specifically designed to be part of a healthcare technology ecosystem, and integrations like this not only simplify implementation but also improve the experience for both users and caregivers."

Benefits of an Integrated Ecosystem
By becoming certified on Enovation UMO, Dosell establishes a unique market position. Offering an integrated solution that handles medication management, alarms, and other care needs within a single platform meets the growing demand for comprehensive solutions in digital healthcare. This not only enhances iZafe's appeal to healthcare providers but also enables its partners to deliver a more competitive and value-driven offering to their customers.

Opening Doors to More Markets
Beyond the Netherlands, this integration also creates opportunities for iZafe to expand into other markets where Enovation UMO is established. With the platform’s presence in 18 countries, iZafe has a unique opportunity to strengthen its international presence and build relationships with new partners and customers.

A Step Forward for iZafe’s Growth Strategy
The certification is part of iZafe’s broader strategy to establish Dosell as a key component of the global healthcare technology landscape. By collaborating with established platforms like Enovation UMO, iZafe demonstrates its commitment to innovation and its ability to meet market demands for integrated and efficient healthcare solutions.

About Enovation Platform
Enovation UMO is part of the Enovation Platform: the leading platform for digital care and collaboration. With over 350 partners worldwide, the platform offers a wide variety of integrations. Enovation Platform uses open software, which connects seamlessly to care organisations' systems and those of their partner organisations. This way, the platform provides all the digital tools care professionals need to support patients or clients – whatever their needs.
https://enovationgroup.com/en/enovation-umo/

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group AB Strengthens Global Position with UMO Certification for Dosell

Enovation UMO Certified Partner

Dosell Secures Large Order for 1,000 Units in the Netherlands – Order Value of SEK 3 Million and Up to SEK 400,000/Month in Recurring Revenue

iZafe Group AB (publ) ("iZafe") announces today that it has received a new confirmed order for an additional 1,000 Dosell units from its exclusive distributor in the Netherlands, TCCN. This strategically important order has a value of approximately SEK 3 million. Deliveries will be split into two batches – 750 units in 2024 and the remaining 250 in the first half of 2025 – laying the foundation for stable licensing revenue of up to SEK 400,000 per month during 2025.

This order ensures that TCCN retains its exclusivity in the Dutch market, in accordance with previously communicated terms.

Once this order and previous ones are fully implemented, they are expected to generate recurring revenue of approximately SEK 400,000 per month in 2025. The order strengthens iZafe's cash flow and builds a long-term revenue model, clearly affirming Dosell's strong position as a leading solution in medication dispensing and a vital tool for the digitalization of the healthcare sector.

Since the beginning of the year, TCCN, which took over the exclusive distribution agreement for Dosell in the Netherlands, has established a dedicated office and showroom for Dosell in Assen. TCCN has successfully positioned Dosell in the rapidly growing Dutch medication dispensing market through partnerships with several leading players, including MobileCare.

"This order and the recurring revenue it generates demonstrate the enormous potential Dosell has to deliver both short-term results and long-term growth. We are impressed with TCCN’s work and view this development as a strategic milestone on our journey to making Dosell the leading solution for medication dispensing in Europe," says Anders Segerström, CEO of iZafe Group.

"The momentum for Dosell in the Dutch market is strong, both in the intramural and extramural market segments. With our gradual product introduction approach and focus on quality, we have built a solid foundation for TCCN’s new business unit. Our customers – healthcare providers for home care and intramural long-term care – appreciate the Dosell’s highly autonomous working, effortless deployment and low cost. We expect a strong growth going forward and this order enables us to meet the demand in the Dutch market during first half of 2025. " says Taeke Castelein, Managing Director of TCCN.

The Dutch market for medication dispensing solutions is in an expansive phase, where digital solutions are becoming increasingly central to improving patient safety and efficiency. Dosell meets these needs with its unique functionality that prevents double dosing and ensures correct medication intake. TCCN’s dedicated efforts have established Dosell as a strong player in this ecosystem, and continued implementation is expected to drive both market share and revenue growth.

For more information about TCCN, visit: https://tccn.eu.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.com

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Dosell Secures Large Order for 1,000 Units in the Netherlands – Order Value of SEK 3 Million and Up to SEK 400,000/Month in Recurring Revenue

Sjalvstandig Medicinering Hemtjanst 2